96 episodes

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s & Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis.
With 1.6 million Americans living with IBD, which includes Crohn’s disease and ulcerative colitis, and approximately 70,000 new cases diagnosed annually, the Crohn’s & Colitis Foundation is dedicated to developing and cultivating IBD healthcare providers through continued education and creation of valuable resources that directly impact the standard-of-care and everyday clinical practices in IBD.
The Crohn’s & Colitis Foundation is the only national organization dedicated to driving efforts in IBD research, education and support for patients, caregivers, and professionals.  The Crohn’s & Colitis Foundation is building initiatives to address high priority areas, and developing the tools, including this educational series, to educate healthcare professionals and meet patients’ needs.  
In Collaboration with

Crohn’s & Colitis Foundation Perspectives ReachMD

    • Science

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s & Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis.
With 1.6 million Americans living with IBD, which includes Crohn’s disease and ulcerative colitis, and approximately 70,000 new cases diagnosed annually, the Crohn’s & Colitis Foundation is dedicated to developing and cultivating IBD healthcare providers through continued education and creation of valuable resources that directly impact the standard-of-care and everyday clinical practices in IBD.
The Crohn’s & Colitis Foundation is the only national organization dedicated to driving efforts in IBD research, education and support for patients, caregivers, and professionals.  The Crohn’s & Colitis Foundation is building initiatives to address high priority areas, and developing the tools, including this educational series, to educate healthcare professionals and meet patients’ needs.  
In Collaboration with

    Endoscopic & Histological Assessment, Correlation, & Relapse in Clinically Quiescent Ulcerative Colitis

    Endoscopic & Histological Assessment, Correlation, & Relapse in Clinically Quiescent Ulcerative Colitis

    Guest: Jordan E. Axelrad, MD, MPH


    Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)
    Mark T Osterman, Frank I Scott, Franz F Fogt, Erin D Gilroy, Susan Parrott, Joseph Galanko, Raymond Cross, Alan Moss, Hans H Herfarth, Peter D R Higgins

    Abstract
    Objective: It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse.
    Design: This multicenter prospective cohort study conducted by the Crohn's and Colitis Foundation Clinical Research Alliance included 100 adults with UC in clinical remission undergoing surveillance colonoscopy for dysplasia. Endoscopic activity was assessed using the Mayo endoscopic score (MES), ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS). Histology was assessed with the Riley ...

    Keeping CALM in Crohn’s Disease: An Exploration of Biomarker Cutoffs & Endoscopic Outcomes

    Keeping CALM in Crohn’s Disease: An Exploration of Biomarker Cutoffs & Endoscopic Outcomes

    Guest: Xiaohong Wang, MD, PhD


    Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study
    Walter Reinisch, Remo Panaccione, Peter Bossuyt, Filip Baert, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, William J Sandborn, Stefan Schreiber, Sofie Berg, Qian Zhou, Kristina Kligys, Ezequiel Neimark, Ahmed A Suleiman, Geert D'Haens, Jean-Frederic Colombel
    Background: CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone. The purpose of this post hoc analysis of CALM was to identify drivers of treatment escalation and evaluate the association between biomarker cutoff concentrations and endoscopic end points.
    Methods: The proportion of patients achieving CD Endoscopic Index of Severity (CDEIS) 4 and no deep ulcers 48 weeks after randomization was evaluated according to CRP 5 mg/L or ≥5 mg/L and FC 250 μg/g or ≥250 μg/g. Subgroup analyses were performed according to disease location, and sensitivity analyses were conducted in patients with elevated CRP and/or FC at baseline. The association between endoscopic end points and biomarker cutoffs was performed using ...

    Crohn’s & Colitis Congress 2021: Getting a Holistic View of IBD Diet Disparities & Well-Being

    Crohn’s & Colitis Congress 2021: Getting a Holistic View of IBD Diet Disparities & Well-Being

    Guest: Tina Aswani Omprakash


    Wellness includes many different aspects, but what about mental health and the stressors of life that affect IBD patients? Joining Dr. Charles Turck to share key takeaways from a session at the 2021 Crohn’s and Colitis Congress called “Holistic View of IBD Diet Disparities and Well-Being” is Tina Aswani Omprakash, patient advocate and co-moderator of the session.

    Crohn’s & Colitis Congress 2021: The Future of IBD Treatments

    Crohn’s & Colitis Congress 2021: The Future of IBD Treatments

    Host: Charles Turck, PharmD, BCPS, BCCCP

    Guest: Siddharth Singh, MD


    Dr. Charles Turck is joined by Dr. Siddharth Singh from the University of California, San Diego, to discuss emerging therapies for inflammatory bowel disease, or IBD, and share some highlights from the session “The Future of IBD Treatments” from Crohn’s & Colitis Congress 2021.

    Crohn’s & Colitis Congress 2021: Challenges & Approaches to Managing IBD in the COVID-19 Era

    Crohn’s & Colitis Congress 2021: Challenges & Approaches to Managing IBD in the COVID-19 Era

    Host: Charles Turck, PharmD, BCPS, BCCCP

    Guest: Frank Scott


    Dr. Charles Turck is joined by Dr. Frank Scott from the University of Colorado School of Medicine to share some highlights from his session, “Challenges and New Approaches to Managing IBD in the COVID-19 Era,” at Crohn’s & Colitis Congress 2021.

    Crohn’s & Colitis Congress 2021: Incorporating IBD Therapies

    Crohn’s & Colitis Congress 2021: Incorporating IBD Therapies

    Host: Charles Turck, PharmD, BCPS, BCCCP

    Guest: Stephen Hanauer, MD


    Dr. Turck joins Dr. Stephen Hanauer of Northwestern University to discuss some of the highlights from his upcoming presentation at the 2021 Crohn’s & Colitis Congress, a Partnership of the Crohn’s and Colitis Foundation and the American Gastroenterological Association.

Top Podcasts In Science

Listeners Also Subscribed To